Home › Modalities › Small Molecule

Small Molecule (89 companies)

Ticker	Company	Therapeutic areas	Programs	Lead stage	Programs
ACIU	AC Immune	Neurology Rare	6	Phase 3	11
ACRS	Aclaris Therapeutics	DermatologyRespiratory	4	Phase 2	7
ACRV	Acrivon Therapeutics	Oncology	5	Phase 2	5
ACTU	Actuate Therapeutics	Oncology	8	Phase 2	8
AGMB	Agomab Therapeutics	ImmunologyRespiratory Rare	2	Phase 2	4
AKBA	Akebia Therapeutics	HematologyOphthalmology+2 Rare	7	Approved	10
ALDX	Aldeyra Therapeutics	DermatologyOncology+1 Rare	8	NDA Submitted	8
ATHE	Alterity Therapeutics	Neurology Rare	2	Phase 3	2
AMLX	Amylyx Pharmaceuticals	MetabolicNeurology Rare	1	Phase 3	5
ANNX	Annexon	HematologyNeurology+2 Rare	1	NDA Submitted	6
RCUS	Arcus Biosciences	DermatologyImmunology+1	2	Phase 3	6
ARDX	Ardelyx	Renal	4	Approved	4
ARVN	Arvinas	NeurologyOncology Rare	15	Approved	15
ATAI	Atai Beckley	Neurology	5	Phase 3	5
BIOA	BioAge Labs	CardiovascularOphthalmology	2	Phase 1	2
BMEA	Biomea Fusion	Metabolic	5	Phase 2	5
BBOT	BridgeBio Oncology Therapeutics	Oncology	8	Phase 1	8
CCCC	C4 Therapeutics	Oncology	2	Phase 2	2
CRDL	Cardiol Therapeutics	Cardiovascular Rare	4	Phase 3	4
CRVO	CervoMed	Neurology Rare	5	Phase 3	5
CING	Cingulate	Neurology	1	NDA Submitted	1
CLNN	Clene	Neurology Rare	5	NDA Submitted	5
CLYM	Climb Bio	HematologyImmunology+1 Rare	1	Phase 2	7
COGT	Cogent Biosciences	HematologyOncology Rare	6	NDA Submitted	6
CGTX	Cognition Therapeutics	Neurology	2	Phase 2	2
CMPS	COMPASS Pathways	Neurology	3	NDA Submitted	3
CRVS	Corvus Pharmaceuticals	DermatologyOncology	3	Phase 3	4
CRNX	Crinetics Pharmaceuticals	MetabolicOncology Rare	6	Approved	6
CGEM	Cullinan Therapeutics	HematologyImmunology+2 Rare	1	NDA Submitted	10
HELP	Cybin	Neurology	3	Phase 3	3
DFTX	Definium Therapeutics	Neurology	4	Phase 3	4
ELOX	Eloxx Pharmaceuticals	Renal Rare	4	Phase 2	4
ENTA	Enanta Pharmaceuticals	DermatologyImmunology+1	6	Phase 3	6
ERAS	Erasca	Oncology	3	Phase 1	4
ETON	Eton Pharmaceuticals	GI/HepatologyMetabolic+1 Rare	9	Approved	14
EVMN	Evommune	DermatologyImmunology+1	4	Phase 2	6
EXEL	Exelixis	CardiovascularOncology	16	Approved	21
EYPT	EyePoint	Ophthalmology	3	Phase 3	3
FHTX	Foghorn Therapeutics	Oncology	1	Phase 1	1
FBIO	Fortress Biotech	DermatologyHematology+1 Rare	6	Approved	12
GANX	Gain Therapeutics	MetabolicNeurology Rare	4	Phase 2	5
GHRS	GH Research	NeurologyWomen's Health	4	Phase 2	4
GOSS	Gossamer Bio	Cardiovascular Rare	4	Phase 3	4
GRCE	Grace Therapeutics	Neurology Rare	3	NDA Submitted	3
IMRX	Immuneering	Oncology	5	Phase 3	5
IMUX	Immunic	GI/HepatologyNeurology	4	Phase 3	4
IBRX	ImmunityBio	Infectious DiseaseOncology	1	NDA Submitted	16
IMNM	Immunome	Oncology	1	NDA Submitted	9
IXHL	Incannex Healthcare	ImmunologyNeurology+1	3	Phase 2	3
KPRX	Kiora Pharmaceuticals	Ophthalmology Rare	5	Phase 2	5
KURA	Kura Oncology	MetabolicOncology	9	Approved	9
KYMR	Kymera Therapeutics	DermatologyRespiratory Rare	4	Phase 2	4
MAIA	MAIA Biotechnology	Oncology	7	Phase 3	7
MIST	Milestone Pharmaceuticals	Cardiovascular	3	Phase 3	3
GLUE	Monte Rosa Therapeutics	CardiovascularDermatology+2 Rare	8	Phase 1	8
NGEN	NervGen Pharma	Neurology	1	Phase 1	4
NRXP	NRX Pharmaceuticals	Neurology	5	NDA Submitted	5
NRIX	Nurix Therapeutics	ImmunologyNeurology+1	15	Phase 2	15
NVCT	Nuvectis Pharma	Oncology	3	Phase 1	3
OCS	Oculis Holding	NeurologyOphthalmology	4	Phase 3	5
OMER	Omeros	HematologyNeurology+2 Rare	2	NDA Submitted	7
IRD	Opus Genetics	Ophthalmology Rare	4	Approved	12
OVID	Ovid Therapeutics	Neurology Rare	6	Phase 1	6
KTTA	Pasithea Therapeutics	NeurologyOncology Rare	4	Phase 1	4
PMVP	PMV Pharmaceuticals	Oncology	7	Phase 2	7
PCSA	Processa Pharmaceuticals	GI/HepatologyOncology+1 Rare	5	Phase 2	7
TARA	Protara Therapeutics	DermatologyMetabolic+1 Rare	1	Phase 3	3
QNRX	Quoin Pharmaceuticals	DermatologyImmunology Rare	8	Phase 2	8
RLMD	Relmada Therapeutics	MetabolicOncology Rare	4	Phase 2	4
RVPH	Reviva Pharmaceuticals	CardiovascularDermatology+2 Rare	10	Phase 3	10
RYTM	Rhythm Pharmaceuticals	Metabolic Rare	1	Approved	13
SGMT	Sagimet Biosciences	DermatologyMetabolic	4	Phase 3	5
SCYX	Scynexis	Infectious Disease	4	Approved	4
SLS	SELLAS Life Sciences Group	Oncology	3	Phase 3	8
GPCR	Structure Therapeutics	MetabolicRespiratory Rare	5	Phase 2	5
TNGX	Tango Therapeutics	Oncology	6	Phase 1	6
TENX	Tenax Therapeutics	Cardiovascular Rare	2	Phase 3	2
TVTX	Travere Therapeutics	MetabolicRenal Rare	6	Approved	7
TTRX	Turn Therapeutics	DermatologyInfectious Disease	3	Phase 3	4
TYRA	Tyra Biosciences	MetabolicOncology Rare	5	Phase 2	5
RARE	Ultragenyx Pharmaceutical	CardiovascularGI/Hepatology+2 Rare	1	Approved	12
UNCY	Unicycive Therapeutics	Renal	2	NDA Submitted	2
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	23	Approved	26
VERA	Vera Therapeutics	Infectious DiseaseRenal Rare	1	Approved	8
VKTX	Viking Therapeutics	GI/HepatologyMetabolic+1 Rare	7	Phase 3	9
VYGR	Voyager Therapeutics	MetabolicNeurology Rare	2	Phase 1	7
VTVT	vTv Therapeutics	MetabolicRespiratory Rare	8	Phase 3	8
XENE	Xenon Pharmaceuticals	Neurology	6	Phase 3	6
ZBIO	Zenas BioPharma	DermatologyImmunology+1 Rare	4	NDA Submitted	11